SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Peter R. Little, Vickie L. King, Kylie R. Davis, Sallie B. Cosgrove, Michael R. Stegemann, A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs, Veterinary Dermatology, 2015, 26, 1
  2. 2
    Vincent Bruet, Blandine Lieubeau, Julie Herve, Anne Roussel, Laëtitia Imparato, Jean-Claude Desfontis, Patrick Bourdeau, Increased numbers of peripheral blood CD34+ cells in dogs with canine atopic dermatitis, Veterinary Dermatology, 2015, 26, 2
  3. 3
    Cherie M. Pucheu-Haston, Domenico Santoro, Petra Bizikova, Melissa N. C. Eisenschenk, Rosanna Marsella, Tim Nuttall, Review: Innate immunity, lipid metabolism and nutrition in canine atopic dermatitis, Veterinary Dermatology, 2015, 26, 2
  4. 4
    Cherie M. Pucheu-Haston, Petra Bizikova, Rosanna Marsella, Domenico Santoro, Tim Nuttall, Melissa N. C. Eisenschenk, Review: Lymphocytes, cytokines, chemokines and the T-helper 1–T-helper 2 balance in canine atopic dermatitis, Veterinary Dermatology, 2015, 26, 2
  5. 5
    Arseniy E. Yuzhalin, Anton G. Kutikhin, Interleukins in Cancer Biology, 2015,

    CrossRef

  6. 6
    Erin E. McCandless, Catherine A. Rugg, Gregory J. Fici, James E. Messamore, Michelle M. Aleo, Andrea J. Gonzales, Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells, Veterinary Immunology and Immunopathology, 2014, 157, 1-2, 42

    CrossRef

  7. You have free access to this content7
    K Kasutani, E Fujii, S Ohyama, H Adachi, M Hasegawa, H Kitamura, N Yamashita, Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice, British Journal of Pharmacology, 2014, 171, 22
  8. 8
    Anja Rabenhorst, Karin Hartmann, Interleukin-31: A Novel Diagnostic Marker of Allergic Diseases, Current Allergy and Asthma Reports, 2014, 14, 4

    CrossRef

  9. 9
    T. Hawro, R. Saluja, K. Weller, S. Altrichter, M. Metz, M. Maurer, Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge, Allergy, 2014, 69, 1
  10. You have free access to this content10
    A. J. Gonzales, J. W. Bowman, G. J. Fici, M. Zhang, D. W. Mann, M. Mitton-Fry, Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy, Journal of Veterinary Pharmacology and Therapeutics, 2014, 37, 4
  11. 11
    Kristine Rossbach, Wolfgang Bäumer, PCR detects bands consistent with the expression of receptors associated with pruritus in canine dorsal root ganglia, Veterinary Dermatology, 2014, 25, 1
  12. 12
    Sallie B. Cosgrove, Jody A. Wren, Dawn M. Cleaver, Kelly F. Walsh, Stacey I. Follis, Vickie I. King, Jezaniah-Kira S. Tena, Michael R. Stegemann, A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis, Veterinary Dermatology, 2013, 24, 6
  13. 13
    Sallie B. Cosgrove, Jody A. Wren, Dawn M. Cleaver, David D. Martin, Kelly F. Walsh, Jessica A. Harfst, Stacey L. Follis, Vickie L. King, Joseph F. Boucher, Michael R. Stegemann, Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis, Veterinary Dermatology, 2013, 24, 5
  14. 14
    Heike Benecke, Tobias Lotts, Sonja Ständer, Investigational drugs for pruritus, Expert Opinion on Investigational Drugs, 2013, 22, 9, 1167

    CrossRef

  15. 15
    Tong Liu, Ru-Rong Ji, New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?, Pflügers Archiv - European Journal of Physiology, 2013, 465, 12, 1671

    CrossRef